NGEN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

4.240

Open

4.200

VWAP

4.10

Vol

52.72K

Mkt Cap

320.81M

Low

4.005

Amount

216.06K

EV/EBITDA(TTM)

Total Shares

79.21M

431.63M

EV/OCF(TTM)

P/S(TTM)

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

Events Timeline

(ET)

2026-03-04

07:50:00

NervGen Pharma Appoints New Executives

2026-02-09 (ET)

2026-02-09

07:20:00

NervGen Pharma Appoints Adam Rogers as CEO

News

5.0

03-04Newsfilter

NervGen Pharma Appoints New Executives to Enhance Leadership Team

8.5

02-18Newsfilter

NervGen Pharma to Participate in Upcoming Investor Conferences

5.0

02-09seekingalpha

NervGen Pharma Appoints New CEO Adam Rogers

8.5

01-08NASDAQ.COM

NervGen Pharma Approved for Nasdaq Listing, Advancing SCI Treatment Drug Development

Valuation Metrics

The current forward P/E ratio for NervGen Pharma Corp (NGEN.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess NervGen Pharma Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding NGEN

Trading Trends

People Also Watch

Frequently Asked Questions

What is NervGen Pharma Corp (NGEN) stock price today?

The current price of NGEN is 4.05 USD — it has decreased -2.41

What is NervGen Pharma Corp (NGEN)'s business?

What is the price predicton of NGEN Stock?

Wall Street analysts forecast NGEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGEN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NervGen Pharma Corp (NGEN)'s revenue for the last quarter?

NervGen Pharma Corp revenue for the last quarter amounts to NaN USD, decreased

What is NervGen Pharma Corp (NGEN)'s earnings per share (EPS) for the last quarter?

NervGen Pharma Corp. EPS for the last quarter amounts to USD, decreased

How many employees does NervGen Pharma Corp (NGEN). have?

NervGen Pharma Corp (NGEN) has 0 emplpoyees as of March 11 2026.

What is NervGen Pharma Corp (NGEN) market cap?

Today NGEN has the market capitalization of 320.81M USD.

NGEN Overview